- Home
- Companies
- Intrommune Therapeutics
- Products
- Intrommune - Model OMIT - Oral Mucosal ...
Intrommune - Model OMIT -Oral Mucosal Immunotherapy for the Treatment of Food Allergies
Intrommune has developed a novel drug delivery platform—oral mucosal immunotherapy (OMIT)—for the treatment of food allergies. Therapeutic agents are embedding in fully functioning toothpaste so that treatment can be conveniently administered during a patient’s daily toothbrushing routine.
OMIT is based on the principle of allergy immunotherapy or “desensitization,” a technique that allergists have used to treat the underlying cause of respiratory allergies for over 100 years. OMIT leverages the unique ability of the lining of the mouth to retrain the immune system (sometimes referred to as “desensitization”) and thus reduce allergic reactions to foods like peanuts over time. Daily use of OMIT toothpaste gradually increases the threshold of allergen that would normally trigger food allergy symptoms – to the point where an allergic person is protected against accidental ingestion of these foods. Research suggests that long-term, daily maintenance therapy is necessary to achieve and maintain this protection. Intrommune’s great-tasting, cavity-fighting OMIT toothpaste makes that easy to do.
